Navigation Links
Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
Date:12/2/2008

on Sunday, December 7, 2008.
  • Study of Coagulation and Platelets Response in an Open Label Randomized Non Treatment and Active Controlled (Dalteparin, Ximelagatran and DU-176b) in 4 Groups of Elderly Healthy Subjects (Abstract 3026), Professor Michel Meyer Samama, Biomnis, Ivry-sur-Seine cedex, France, Satoshi Kunitada, Daiichi Sankyo Pharma Development, Edison, New Jersey, A. Oursin, Biomnis, Ivry-sur-Seine cedex, France, Francois Depasse, Biomnis, Ivry-sur-Seine cedex, France and Nazneen Haque, Daiichi Sankyo Development Ltd., Gerald Cross, Buckinghamshire, United Kingdom. This will be a poster presentation on Monday, December 8, 2008.
  • To arrange an interview with Francis Plat, MD, vice president, clinical development at Daiichi Sankyo Pharma Development, or Jeffrey Weitz, MD, FACP, FRCP, Professor of Medicine and Biochemistry, McMaster University and Director, Henderson Research Centre, Hamilton, Ontario at the 2008 ASH Meeting in San Francisco, please contact Kim Wix, Daiichi Sankyo, at 973-695-8338 (office) 908-656-5447 (mobile) or Catherine Falcetti, MS&L, at 212-468-4337 (office) or 646-246-1843 (mobile).

    About DU-176b

    DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism.

    About Daiichi Sankyo, Inc.

    A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiovascular disease, includ
    '/>"/>

    SOURCE Daiichi Sankyo, Inc.
    Copyright©2008 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine news :

    1. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
    2. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
    3. Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
    4. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
    5. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
    6. Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference
    7. In Support of World AIDS Day, FHSSA Announces New Partnerships That Include the First In-Country Partnerships in Namibia and The Gambia
    8. EMS Magazine Announces Top Innovation Awards for 2008
    9. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
    10. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
    11. Transition Therapeutics Announces Dates for Upcoming Corporate Events
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... 16, 2014 Cloud based mobile ... (HLS) & UStream API’S to serve m3u8 streams on ... for broadcasting live video events with hundreds of thousands ... The App Builder is known for making beautiful and ... BlackBerry and Windows 8 and already over 100,000 apps ...
    (Date:9/16/2014)... serve of dairy food may reduce the risk of ... foods have not traditionally formed part of the diet. ... by Emeritus Professor Mark Wahlqvist from Monash University,s Department ... Institute, considered the role increased consumption of dairy foods ... longevity. , "In a dominantly Chinese food culture, ...
    (Date:9/16/2014)... other workplace incident, a statistic that transport safety experts ... hosted by QUT,s Centre for Accident Research & Road ... Transport Conference (OSIT) to be held on the Gold ... from all facets of transport safety including roads, rail, ... , CARRS-Q research fellow Darren Wishart said the aim ...
    (Date:9/16/2014)... Definitive Healthcare , the leading ... is pleased to announce the release of its ... available for subscription, features detailed hospital profiles that ... , The Canadian database spans Canada’s ten providences ... 750 hospitals. Each hospital profile provides data ...
    (Date:9/16/2014)... The Muscular Dystrophy Association is offering assistance ... affected by muscle disease, including muscular dystrophy, amyotrophic ... MDA offers this service annually for adults and ... compromised respiratory function — including difficulty coughing or ... increased risk of serious and possibly life-threatening complications ...
    Breaking Medicine News(10 mins):Health News:A heart-felt need for dairy food 2Health News:CARRS-Q Host International Transport Safety Conference 2Health News:Canadian Hospital Database Now Offered by Definitive Healthcare 2Health News:MDA Offers Flu Shots to Those Affected by Muscle Disease 2
    ... , , BETHESDA, ... innovative voice data solutions, today announced the availability of ... NotifierRx will help hospitals improve standards of care and ... interactive voice-controlled services. , , NotifierRx ...
    ... , , , ... Kaiser Permanente has launched its sixth season of the Thrive advertising ... health care organization,s commitment to the total health of its members ... new ads -- "Emerald Cities" and "Connected" -- illustrate Kaiser Permanente,s ...
    ... , , , ... NTRI ), a leading provider of weight management programs ... offer consumers striving for a late-summer shape up, some easy, top-of-mind tips ... , , According to Sansone, there ...
    ... Industry Veteran to Lead PI Pharmaceutical Business Unit ... Physicians Interactive LLC (PI), a leader in digital sales and marketing ... Pingle has been named President of PI. Pingle will report to ... lead the company,s pharmaceutical business unit. , , ...
    ... be wary when walking around parking lots, crossing streets ... disturbing research to kick off the school year: A ... near schools is distracted. , A whole variety of ... eating, smoking and even reading -- are keeping drivers ...
    ... , , PITTSBURGH, Sept. 1 Mylan ... subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP ... launched the product, will market this product with 180 days ... is indicated for the treatment or prevention of bronchospasm in ...
    Cached Medicine News:Health News:Audiopoint Adds Voice to Healthcare Reform Debate 2Health News:Audiopoint Adds Voice to Healthcare Reform Debate 3Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 2Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 2Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 3Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 4Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 5Health News:Walk the Weight Off with Shape Up Tips from Leading National Walking Expert Leslie Sansone and Nutrisystem 6Health News:Physicians Interactive Names Sanjay Pingle President 2Health News:Physicians Interactive Names Sanjay Pingle President 3Health News:Drivers Distracted When Near Schools 2
    (Date:9/16/2014)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... for solid tumor cancers, announced today that its DCVax-L ... a "Promising Innovative Medicine" (PIM) under the new "Early ... in April 2014.  A PIM is the first step ... the EAMS.  The PIM designation for ...
    (Date:9/16/2014)... OKLAHOMA CITY , Sept. 16, 2014 ... biopharmaceutical company developing novel orally active drugs ... existing antibiotics, announced today a $1.4 million ... investing arm of life sciences accelerator Accele ... from i2E, Inc., a nationally recognized private ...
    (Date:9/16/2014)... CALGARY, Alberta , Sept. 16, 2014 /PRNewswire/ ... $1.4 billion industry in less than two years, ... along the way. A huge opportunity exists for ... Today, Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind ... providers based on years of clinical research linking ...
    Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
    ... DIEGO, June 10, 2011 Volcano Corporation (NASDAQ: ... precision intravascular diagnosis and therapy guidance tools designed to ... said today that it will be participating in the ... on Thursday, June 16. The presentation by ...
    ... Accuray Incorporated (Nasdaq: ARAY ), a global leader ... have approved the proposed acquisition of TomoTherapy Incorporated (Nasdaq: ... 98 percent of votes cast and 79 percent of shares ... anticipate the closing of the transaction will occur within one ...
    Cached Medicine Technology:TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 2TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 3TomoTherapy Shareholders Approve Accuray Acquisition of TomoTherapy 4
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: